EP
Eversept Partners Portfolio holdings
AUM
$992M
This Quarter Return
-8.54%
1 Year Return
+2.54%
3 Year Return
+103.47%
5 Year Return
+181.01%
10 Year Return
–
AUM
$884M
AUM Growth
+$884M
(-8.8%)
Cap. Flow
-$8.84M
Cap. Flow
% of AUM
-1%
Top 10 Holdings %
Top 10 Hldgs %
58.82%
Holding
75
New
11
Increased
22
Reduced
21
Closed
18
Top Buys
| 1 |
Syndax Pharmaceuticals
SNDX
|
$47.5M |
| 2 |
Neurocrine Biosciences
NBIX
|
$18.5M |
| 3 |
Vaxcyte
PCVX
|
$16.2M |
| 4 |
Glaukos
GKOS
|
$15.6M |
| 5 |
Community Health Systems
CYH
|
$15.2M |
Top Sells
| 1 |
GSK
GSK
|
$40.2M |
| 2 |
Inspire Medical Systems
INSP
|
$17.2M |
| 3 |
Viatris
VTRS
|
$15.8M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$12.8M |
| 5 |
Edwards Lifesciences
EW
|
$12.6M |
Sector Composition
| 1 | Healthcare | 98.66% |
| 2 | Financials | 0.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Natera
NTRA
$23.1B
| $126M | 12.84% | 893,721 +16,955 | +2% | +$2.4M |
|
|
2
GSK
GSK
$79.9B
| $102M | 10.32% | 2,623,246 -1,038,522 | -28% | -$40.2M |
|
3
HCA Healthcare
HCA
$94.5B
| $52.7M | 5.35% | 152,502 -23,306 | -13% | -$8.05M |
|
|
4
Syndax Pharmaceuticals
SNDX
$1.41B
| $51.7M | 5.26% | 4,212,270 +3,868,870 | +1,127% | +$47.5M |
|
5
Vera Therapeutics
VERA
$1.38B
| $45.6M | 4.63% | 1,898,804 +298,789 | +19% | +$7.18M |
|
6
Revvity
RVTY
$10.5B
| $31.6M | 3.21% | 299,087 -93,431 | -24% | -$9.89M |
|
7
HealthEquity
HQY
$7.72B
| $31.1M | 3.16% | 351,976 -34,721 | -9% | -$3.07M |
|
|
8
Inspire Medical Systems
INSP
$2.77B
| $29.7M | 3.02% | 186,425 -107,877 | -37% | -$17.2M |
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $26.5M | 2.69% | 547,116 -131,671 | -19% | -$6.37M |
|
|
10
Community Health Systems
CYH
$387M
| $22.8M | 2.32% | 8,458,020 +5,631,020 | +199% | +$15.2M |
|
11
ZimVie
ZIMV
$532M
| $22.5M | 2.28% | 2,079,380 +8,600 | +0.4% | +$92.9K |
|
|
12
Teva Pharmaceuticals
TEVA
$21.1B
| $21.7M | 2.2% | 1,410,765 -831,360 | -37% | -$12.8M |
|
|
13
Vaxcyte
PCVX
$4B
| $21M | 2.14% | 557,070 +429,482 | +337% | +$16.2M |
|
14
Bruker
BRKR
$5.16B
| $20.8M | 2.12% | 499,207 +264,273 | +112% | +$11M |
|
15
Centene
CNC
$14.3B
| $20.7M | 2.1% | 340,339 +151,846 | +81% | +$9.22M |
|
16
Viridian Therapeutics
VRDN
$1.5B
| $18.6M | 1.89% | 1,377,674 +597,676 | +77% | +$8.06M |
|
|
17
Neurocrine Biosciences
NBIX
$13.8B
| $18.5M | 1.88% | +167,243 | New | +$18.5M |
|
18
United Therapeutics
UTHR
$13.8B
| $17.7M | 1.8% | 57,489 +13,786 | +32% | +$4.25M |
|
19
Bio-Techne
TECH
$8.5B
| $16.4M | 1.67% | 280,117 -19,193 | -6% | -$1.13M |
|
20
BioCryst Pharmaceuticals
BCRX
$1.74B
| $16.3M | 1.65% | 2,172,436 +192,124 | +10% | +$1.44M |
|
|
21
Glaukos
GKOS
$5.5B
| $15.6M | 1.59% | +158,957 | New | +$15.6M |
|
22
Ionis Pharmaceuticals
IONS
$6.8B
| $15.6M | 1.58% | 517,021 +302,069 | +141% | +$9.11M |
|
23
Travere Therapeutics
TVTX
$1.56B
| $14.6M | 1.49% | 816,254 +325,958 | +66% | +$5.84M |
|
24
Globus Medical
GMED
$8.27B
| $14.1M | 1.43% | +192,893 | New | +$14.1M |
|
25
Celldex Therapeutics
CLDX
$1.47B
| $12.6M | 1.28% | 696,499 -23,337 | -3% | -$424K |
|